Aims: Current therapies in Parkinson's disease mainly treat symptoms rather than provide effective neuroprotection. We examined the effects of safinamide (monoamine oxidase B and sodium channel blocker) on microglial activation and the degeneration of dopaminergic neurons in a rat model of PD in vivo, and on microglia in vitro. Methods: Rats received unilateral stereotaxic injection of 6-hydroxydopamine into the medial forebrain bundle on day 0: the contralateral side served as control. Safinamide or vehicle were delivered from days 0 or 1, for 7 days, via subcutaneous mini-pumps. Results: In vehicle-treated rats 6-hydroxydopamine caused a significant increase in the number of activated MHC-II + microglia compared with the contralateral side, and only 50% of the dopaminergic neurons survived in the ipsilateral SNc. In contrast, rats treated daily with safinamide 50 and 150 mg/ml (on day 0 or 1) exhibited a significantly reduced number of activated microglia (55% reduction at 150 mg/ml) and a significant protection of dopaminergic neurons (80% of neurons survived) (p<0.001) compared with vehicle-treated controls. Rasagiline, a monoamine oxidase B inhibitor, and lamotrigine, a sodium channel blocking drug, also protected dopaminergic neurons, indicating that safinamide may act by either or both mechanisms.
Introduction
Degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) is one of the pathological hallmarks of Parkinson's disease (PD). Multiple factors including: oxidative stress [1] , excitotoxicity [2] , mitochondrial dysfunction [3] and inflammation [4] may be involved in the initiation and progression of pathology in PD, so drugs with multiple modes of action may be of particular value for neuroprotective therapy.Safinamide is approved in the EU for use in combination with dopamine agonists as a symptomatic therapy in PD. Safinamide's pharmacological activities include selective blockade of state-dependent voltage-gated sodium channels [5] , inhibition of induced glutamate release in vitro and reversible inhibition of monoamine oxidase-B (MAO B) [6] . This pharmacological profile has suggested possible symptomatic benefits in PD, by increasing DA availability through inhibition of its metabolism by brain MAO-B [6] , and neuroprotective benefits through reduction of sodium influx and excitotoxic glutamate release [6] . More recently there has been an appreciation of the role of blockers of voltage gated sodium channels on the activation of microglia [7] [8] , combined with the demonstration that safinamide can markedly reduce microglial activation and neuroinflammation in animal models of multiple sclerosis [9] . These observations suggest an additional potential role for safinamide in the therapy of PD, and other neurodegenerative diseases with significant microglial involvement. In this report we investigate the effects of safinamide in a widely used animal model of PD in which both neuroinflammation and neurodegeneration are induced in the SN by focal delivery of the neurotoxin 6-hydroxydopamine . In vitro studies with purified microglia were used to establish a direct effect of safinamide on these cells. The results suggest that both the sodium channel and MAO-B activities of safinamide may contribute to a unique profile of efficacy, and that safinamide therapy protects against neurodegeneration, in addition to any symptomatic effects.
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Methods

6-OHDA lesion induction
Male Sprague-Dawley rats (Harlan Ltd, UK), 200-230 g on the day of surgery, were housed five rats per cage and kept on a 12-h light/dark cycle, with food and water ad libitum. On arrival animals were allowed to acclimatize to the new environment for seven days before any experiments were conducted. Lesions were induced by stereotactic injection of 6-OHDA-hydrogen bromide free base (12 μg in final injection volume of 4 μl in 0.1% ascorbic acid/saline solution) into the left medial forebrain bundle (mfb), under isoflurane-anesthesia as previously described [10] using the following coordinates for the location of the mfb: 2.2 mm posterior, 1.5 mm lateral from bregma, and 7.9 mm ventral to the dura, according to the brain atlas of Paxinos and Watson (1986). The contralateral side served as an uninjected control. All experiments were performed in accordance with the UK Home Office Animals (Scientific Procedures) Act (1986) and approved by the local ethics committee (University College London).
Drug treatment regimens
Two treatment regimens were employed. For the first study, animals received a stereotactic injection of 6-OHDA into the left mfb as described above. The animals were divided randomly into three groups (n=6-8 per group) and, to ensure consistent drug levels, subcutaneous osmotic minipumps were implanted (delivery rate: 10 l/hr, 7 days duration) (ALZET, Cupertino, CA), containing safinamide 50 or 150 mg/ml, or distilled water as vehicle (calculated delivery of 12 mg/day or 36 mg/day). Drug/vehicle release from the pumps is reported by the manufacturer to start 24 hours after implantation. The doses were chosen based on previous assays of the blood serum concentration (1.4-13.5 µM) of the drug following administration of safinamide by minipump in rats for 7 consecutive days in which it was observed that the drug reduced neuroinflammation and provided neuroprotection in another model when plasma levels were maintained above 10 µM [9] , consistent with a sodium channel blocking mechanism (IC50 2-10 µM). These doses are clinically efficacious and tolerated in patients [6] . Safinamide/vehicle treatment (subcutaneous osmotic minipumps as before) was administered for seven consecutive days starting on the same day (day 0) as 6-OHDA lesion induction, and on day eight after 6-OHDA lesion induction the animals were killed under terminal anaesthesia by perfusion fixation. A seven-day dosing regimen after 6-OHDA lesioning was chosen because this duration covers the period over which the majority of DA neurons
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degenerate, and a high number of activated microglial cells are observed [10] . To validate the findings the first study (see above) was repeated.
For the second study, animals received a stereotactic injection of 6-OHDA into the left mfb as described above, and they were then divided randomly into two groups (n=6 per group). On the following day (day 1) osmotic mini-pumps (seven day duration, Alzet, Cupertino, CA) containing safinamide 150 mg/ml and/or vehicle were implanted sub-cutaneously and treatment was continued for seven consecutive days prior to sacrifice on day nine after 6-OHDA lesion induction. This study was designed to start safinamide treatment after a delay of 48 hours, to rule out possible drug interaction with 6-OHDA (which has a short half-life due to rapid oxidation). The dose of safinamide was chosen based on our finding from the first experiment (see results).
Safinamide combines activity against both MAO B and sodium channels, and so to determine whether the effects of safinamide in the preceding studies could be ascribed to one or the other mechanism a third experiment was performed to compare the results obtained above with those obtained from dosing with the MAO B inhibitor rasagiline, and, in a separate group of animals, with the sodium channel blocking agent lamotrigine. Male SD rats (200-230 g, n=18) were injected on day zero with 6-OHDA into the medial forebrain bundle as described above. The animals were divided randomly into three equal groups and, on day two, therapy was initiated with rasagiline (1 mg/kg one loading dose p.o., followed by 0.5 mg/kg, p.o. once daily for seven consecutive days (see [11] ). To select a therapeutically relevant dose for rasagiline reference was made to human therapeutic and animal model data. Because of the irreversible mode of inhibition of rasagiline on monoamine oxidases, a low daily dose is used to accumulate significant inhibition of MAO-B without troublesome effects on MAO-A. Thus the recommended dose in PD therapy is 1 mg per day (approximately 0.015 mg/kg). In several reports on studies in rat models rasagiline has been reported affect biochemical and cellular processes in the CNS at doses ranging from 0.05 mg/kg/day [12] through 0.5 mg/kg/day [13] , to 1 and 3 mg/kg/day [14] . Lamotrigine (10 mg/kg p.o. once daily for seven days) or vehicle (0.5 % methylcellulose p.o. once daily for seven days). All animals were killed by perfusion fixation (see below) while under deep terminal anaesthesia 9 days after the 6-OHDA lesion induction. The doses selected for lamotrigine and rasagiline were based on previous reports showing neuroprotective properties in rodent models of PD and clinically relevant and safe circulating concentrations in patients [15, 16] . The adoption of different routes of drug administration
was necessary due to lack of comparable data linking dose and circulating concentration for the different agents.
Tissue fixation and collection
At the end of each individual experiment animals were perfused transcardially with cold, phosphate-buffered saline (PBS 0.1M) followed by perfusion fixation with cold (4ºC) paraformaldehyde (4% in 0.1M PBS, pH 7.4). Brains were transferred to 4% paraformaldehyde solution (4% in 0.1M PBS, pH 7.4) and kept for 24-48 hours prior to cryoprotection in sucrose solution (30% in 0.1M PBS, containing sodium azide (0.1%) as preservative) until the block sank (48-72 hours). Coronal sections (20 µm thick) were cut throughout the entire SN using a cryostat and collected as free floating specimens.
Immunohistochemical assessment of dopaminergic neuronal degeneration and microglial activation
Dopaminergic neurons were identified by the immunohistochemical detection of tyrosine hydroxylase (TH), as described previously [10] . Briefly, endogenous peroxidase activity in the nigral free-floating sections was blocked by incubation in H 2 O 2 (1%) for 30 min. Bound antibody was visualized utilizing 3, 3′-diaminobenzidine and hydrogen peroxide substrate. Activated microglia were distinguished by the expression of major histocompatibility complex II (MHC-II, OX-6 labeling), using a similar protocol to that described for TH, with the following amendments. Non-specific binding was blocked with normal horse serum (5% in PBS), and the monoclonal antibody directed against OX-6 (Abcam, UK) was made up in normal horse serum (1%) (Sigma) in a dilution of 1:750. The biotinylated secondary antibody was rat-adsorbed mouse monoclonal (Sigma).
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Image capture and cell counts
Cell counts were conducted manually using photomicrographs prepared using a light microscope connected to a Nikon D300 camera at 10x (objective) magnification. To ensure non- 
Statistical analysis of the data
The data are presented as mean ± SEM. Statistical significance was calculated by two-way analysis of variance (ANOVA) and post-tested with post-hoc parametric Newman-Keuls Multiple
Comparison test using GraphPad Prism v5.00 (GraphPad software, USA) software. Differences within and between groups were considered statistically significant at p <0.05.
In vitro studies
Animals and materialsSprague Dawley rat pups (5-6 day old) were bred and reared in house from stock animals (Charles River UK, Kent, UK), and were sacrificed in accordance with schedule 1 of the Animals Scientific Procedures Act (1986) UK. Primary cultures of rat microglia and primary cultures of mixed glia-cerebellar granule neurons were prepared and seeded as previously described [18] .The cells were used after 1 day in vitro (DIV; microglia) or at least 7 DIV (glialneuronal cultures). Cell culture materials were from Invitrogen (Paisley, UK), FITC-conjugated isolectin B4 (ILB4) a marker of microglia [19] , was from Sigma and anti-arginase-1, a marker for the M2 microglial phenotype characterized as a protective, regenerative phenotype (16;17) was from Santa Cruz Biotech (USA).
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Cell treatment
Microglia were treated with safinamide (0.2-200 μM) or vehicle solvent (dd sterile H2O) ± lipopolysaccharide (LPS, final concentration 2 μg/ml) for 24 h. We used LPS as an activator of microglia as in vivo injection of LPS into the SNc or the striatum has been shown to produce a highly appropriate animal model for Parkinson's disease [20] [21] [22] . For immunofluorescence analysis of arginase-1 and ILB4 expression, treated microglia were processed using standard immunolocalisation protocols, the nuclei counterstained with DAPI, and images captured with a Zeiss Axioskop fluorescence microscope and x40 objective, with images captured under the same exposure conditions for all fields using Axiovision software. The labelled cells were present in the medial and lateral portions of the SNc and they showed hypertrophied cell bodies and shortened processes. Treatment with safinamide at low dose (50 mg/ml for seven consecutive days starting on the same day as 6-OHDA lesion) had no significant effect on the number of activated microglia, but treatment with safinamide at high dose (150 mg/ml) caused a significant reduction (by approx. 45%) in the number of activated cells compared with vehicle-treated control animals (Fig 2B) . In animals treated with safinamide at either low or high dose following 6-OHDA lesion induction, the microglial cells exhibited smaller cell bodies and more ramified processes than in vehicle-treated controls (Fig 2B inset) .
Delayed administration of safinamide protects TH+ve dopaminergic neurons and reduces the number of activated microglia in the SNc following 6-OHDA lesion induction
To avoid the possibility that the neuronal and microglial protection was an artefact resulting from an unexpected interaction between safinamide and 6-OHDA, the implantation of the minipumps was delayed by 24 hours after 6-OHDA injection, thereby allowing an effective drugfree period of 48 hours in which the lesion could develop (see methods). In control animals, injection of 6-OHDA resulted in the degeneration of approximately 50% of the DA neurons (p<0.001), as described above, but even the delayed administration of safinamide at high dose (150 mg/ml; low dose was not employed) still provided significant neuronal and microglial protection.
Thus safinamide-treated animals possessed significantly more surviving DA neurons than controls lacking safinamide (50% increase; p<0.01) (Fig 3A) , and significantly fewer activated (OX6 + ) microglial cells (p=<0.01) (Fig 3B) . As before, the microglial cells in safinamide-treated animals also had a less activated morphological phenotype.
Effects of reference molecules rasagiline and lamotrigine on the survival of DA neurons and the activation of microglial cells
Rasagiline and lamotrigine were employed as relatively specific inhibitors of MAO B and sodium channels respectively, for comparison with safinamide. As before, the injection of 6-OHDA caused the degeneration of approximately 50% of DA neurons on the ipsilateral side (p<0.001; Fig   4A) , but daily administration of rasagiline starting one day after 6-OHDA injection provided significant protection resulting in a 50% increase in the number of surviving neurons (p<0.01).
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Interestingly, rasagiline also provided a significant reduction in the number of activated microglial cells (p<0.001) (Fig 4B) . Similarly, lamotrigine therapy provided significant neuronal protection, with an increase of 37% in the number of surviving neurons (p<0.01) (Fig4A). Lamotrigine treatment also resulted in significantly fewer OX6 + microglial cells within the lesion (p<0.001) (Fig   4B) , and the microglial cells exhibited a less activated morphological phenotype (Fig 4C) .
Neuroprotective effect of safinamide in vitro
Incubation of mixed neuronal-glial cultures with safinamide (0.2 -20.0 μM) had no detrimental effect on cell survival; thus there was no statistically significant difference between cells cultured with or without safinamide. In fact the highest dose of safinamide used appeared to enhance cell survival above controls (Fig 5) .
Incubation of the neuronal-glial cultures with 2 μg/ml LPS induced significant cell death after 24 h, but this was attenuated to control levels by 2-20.0 μM safinamide. Incubation of primary rat cultured microglia with 2 μg/ml LPS for 24 h reduced the expression of arginase 1 observed in control, non-stimulated microglia (Fig 6) . However incubation of primary cultured microglia with 2 μg/ml LPS in the presence of 2μM safinamide promoted enhanced arginase expression as revealed by immunofluorescence. The co-labelling of the cultures with ILB4 was used to confirm that the cells were microglia.
Discussion
In PD, the underlying neurodegenerative processes continue even in treated patients, leading to increasingly drastic losses of vulnerable cells and synapses, and disability that cannot be adequately controlled with current drugs. The need for treatments that will reduce the underlying cell loss is widely recognized. Some compounds have been shown to be effective in toxin-induced models of DA neuron degeneration, and although none has yet been accepted to provide significant neuroprotection in PD patients, a "delayed start" clinical study has suggested that rasagiline treatment may have had an effect on disease progression [24] . Thus there is a need for drugs with additional neuroprotective activities. The results described above show that microglial activation and DA neuron loss can both be reduced by administration of activity-dependent sodium channel blockers (lamotrigine and safinamide), and MAO B inhibitors (rasagiline and safinamide). A single agent combining both of these activities might therefore have potential for long-term benefits in PD and other neurodegenerative diseases with involvement of microglial activation.
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This article is protected by copyright. All rights reserved. We compared the effect of safinamide in the 6-OHDA model with rasagiline, a MAO-B inhibitor commonly used in PD therapy. Rasagiline administered at 0.5 mg/kg daily p.o. showed similar effects on the loss of TH neurons and microglial activation to those of high dose safinamide.
It is thus possible that MAO-B inhibition is part of the neuroprotective mechanism of safinamide.
However since a MAO-B-independent neuroprotective mechanism has been postulated for rasagiline
[35], further investigation is necessary before the role of MAO-B inhibition in the microglial and neuroprotective effects reported here for safinamide are fully understood.
The findings show that treatment with high dose safinamide not only protected DA neurons, but also significantly reduced inflammation as assessed by a measure of microglial activation, namely the expression of MHC class II. In this study we did not assess whether the microglial activation preceded the neuronal degeneration or whether it occurred in response to it, but we have previously reported that following 6-OHDA lesion induction microglial activation occurred within 3 days whereas neuronal loss was detected from day 7 following lesioning [10] . This finding therefore
indicates that the anti-inflammatory effect of safinamide may be a direct effect on microglia. Low 
Neuroprotection is one of the unmet needs in PD and current therapies do not address the progressive neurodegenerative process. Our data show that in addition to modulating the symptoms in patients [43] , safinamide also protects DA neurons and reduces inflammation in the 6-OHDA model of PD. We note that safinamide is now approved for use in PD therapy in Europe and that it is well tolerated in these patients at a similar plasma concentration to that shown to be neuroprotective in the current study. 
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